YOLFTbeta
68

Allgens Medical Technology Co. Ltd. A

688613 · SHG · Healthcare / Medical Devices

8.10CNY-0.30 (-3.57%)

Price History

Full chart

Market Stats

Previous Close8.40
Open8.33
Day Range7.95 – 8.40
52-Week Range12.91 – 29.71
Volume12.19M
Market Cap2.75B
P/E (TTM)335.00
Forward P/E0.00
EPS0.06
Dividend Yield0.15%
Beta0.59
50-Day Avg15.96
200-Day Avg19.14

About

Allgens Medical Technology CO., LTD. engages in the research and development, production, and sale of biomedical materials and related medical device products in China. The company offers biomimetic mineralized collagen artificial bone repair products, including Gejin, Chibei, and Lurui, as well as Aoyu Ning; tissue regeneration and repair products; and absorbable collagen hemostatic sponge products. Its products include isometal, cranial ulcer, teeth, dental implants, and bongold. The company was founded in 2004 and is based in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Menglong Cui
  • Employees271
  • Headquarters3rd Floor, Building 35, Phase 2, Beijing, China, 102609, China
  • Websitehttps://www.allgensmed.cn

Leadership

  • Mr. Menglong CuiGM & Director · b. 1978
  • Mr. Fuzhai CuiFounder & Chief Scientist · b. 1945
  • Ms. Wanlan HuangFounder, Deputy GM & Director · b. 1943
  • Ms. Ling WangHead of Finance · b. 1978
  • Mr. Tianxi SongDirector, Deputy GM & Core Technical Personnel · b. 1981
  • Mr. Guofeng TianDeputy GM & Director · b. 1982
  • Mr. Zhiye QiuDeputy GM, Secretary of the Board of Directors & Core Technical Personnel · b. 1984
  • Xiaoying MiaoAccounting Supervisor
  • Mr. Yongqiang WuChairman of the Board of Supervisors & Human Resource Director · b. 1976

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue91.38M123.69M168.59M183.76M236.06M245.31M226.48M206.03M223.51M
Growth (%)-+35.36%+36.30%+9.00%+28.46%+3.92%-7.68%-9.03%+8.48%
Cost of Revenue18.59M20.81M28.85M29.96M35.62M40.79M39.24M59.40M70.12M
Gross Profit72.79M102.88M139.74M153.80M200.44M204.51M187.24M146.63M223.51M
Gross Margin79.66%83.18%82.88%83.70%84.91%83.37%82.67%71.17%100.00%
Operating Expense45.32M68.08M65.29M51.61M65.53M108.20M138.24M153.99M210.90M
Operating Income27.47M34.80M74.45M102.19M134.91M96.32M48.99M-7.36M12.60M
Operating Margin30.06%28.13%44.16%55.61%57.15%39.26%21.63%-3.57%5.64%
EBITDA32.07M40.19M86.10M114.70M146.24M112.26M67.03M11.06M29.91M
EBITDA Margin35.10%32.49%51.07%62.42%61.95%45.77%29.60%5.37%13.38%
Net Income23.53M32.99M67.78M88.94M120.78M95.22M54.23M-12.66M13.15M
Net Income Margin25.75%26.67%40.21%48.40%51.17%38.82%23.95%-6.15%5.88%
R&D12.36M18.02M22.49M16.01M33.23M57.46M45.50M38.77M39.25M
R&D as % of Total Revenue13.53%14.57%13.34%8.71%14.08%23.42%20.09%18.82%17.56%
Interest Expense310.62K47.87K1.32M1.31M3.44M1.89M3.15M2.98M2.38M
Interest Expense % of Total Revenue0.34%0.04%0.79%0.71%1.46%0.77%1.39%1.45%1.06%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets320.47M525.10M716.08M804.93M1.43B1.46B1.53B1.54B1.56B
Total Liabilities8.27M73.40M152.32M153.25M155.49M133.50M122.61M119.20M116.52M
Total Equity312.20M438.46M532.95M622.67M1.24B1.30B1.38B1.40B1.43B
Cash13.03M86.23M75.42M21.12M411.31M259.87M161.25M156.71M169.07M
Total Debt--46.52M52.13M80.63M61.59M53.42M52.35M-
Net Debt-13.03M-86.23M-28.90M31.01M-330.67M-198.29M-107.84M-104.36M-

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow33.19M79.73M88.45M84.88M129.76M102.05M51.68M-19.60M39.49M
Investing Cash Flow-223.18M-101.06M-206.49M-143.28M-229.49M-197.39M-118.08M14.22M-
Financing Cash Flow179.69M94.00M107.23M4.23M490.21M-55.79M-32.22M1.05M-
Capital Expenditure30.65M99.52M77.14M56.40M61.22M45.42M21.90M13.43M28.93M
Free Cash Flow2.54M-19.79M11.30M28.47M68.54M56.63M29.78M-33.03M10.56M
Dividends Paid310.62K-1.68M1.40M1.24M36.27M14.04M10.78M2.28M
FCF to OCF7.66%-24.83%12.78%33.55%52.82%55.49%57.62%168.49%26.75%
Dividend Paid to FCF12.21%-14.86%4.91%1.81%64.04%47.16%-32.63%21.59%

Earnings

Report DateOct 28, 2021Feb 25, 2022Apr 27, 2022Aug 29, 2022Oct 25, 2022Dec 31, 2022Apr 20, 2023
EPS Estimate-------
EPS Actual0.480.270.100.150.240.230.23
Surprise-------
TimingPre-marketAfter-hoursPre-marketPre-marketAfter-hours-Pre-market

Key Statistics & Ratios

Market Cap2.75B
Enterprise Value1.93B
Trailing P/E335.00
Forward P/E0.00
Price / Sales12.09
Price / Book2.03
EPS0.06
Book Value10.49
Revenue (TTM)227.76M
Gross Profit (TTM)156.17M
EBITDA16.81M
Profit Margin3.78%
Operating Margin-5.63%
Return on Equity0.36%
Return on Assets-0.20%
Shares Outstanding137.01M
Shares Float99.42M
Beta0.59
Dividend Yield0.15%
Dividend Rate0.03
Payout Ratio0.00%

Dividends

20261×
0.03Aug 6, 2026
20241×
0.06Jul 9, 2024
20231×
0.11Jul 6, 2023
20221×
0.27Jul 14, 2022